Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Brown TM, Vera-Llonch M, Kanu C, Sikora Kessler A, Yarlas A, Fehnel SE. Cross-sectional quantitative evaluation of a novel patient-reported outcome measure in familial chylomicronemia syndrome. Patient Relat Outcome Meas. 2024 Feb 15;15:45-59. doi: 10.2147/PROM.S441583
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Khan AH, Kosa K, De Prado Gomez L, Whalley D, Kamat S, Clark M. Content validation of patient-reported sleep measures and development of a conceptual model of sleep disturbance in patients with moderate-to-severe, uncontrolled asthma. Patient Relat Outcome Meas. 2023 Mar 23;14:57-71. doi: 10.2147/PROM.S392666
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Goode AP, Schwartz TA, Kraus VB, Huebner JL, George SZ, Cleveland RJ, Gracely R, Jimenez M, DeFrate LE, Chen J, Golightly YM, Jordan JM. Inflammatory, structural, and pain biochemical biomarkers may reflect radiographic disc space narrowing: The Johnston County Osteoarthritis Project. J Orthop Res. 2020 May;38(5):1027-37. doi: 10.1002/jor.24534
Coles T, Chen K, Nelson L, Harris N, Vera-Llonch M, Krasner A, Martin S. Psychometric evaluation of the hypoparathyroidism symptom diary. Patient Relat Outcome Meas. 2019 Jan 29;2019(10):25-36. doi: 10.2147/PROM.S179310
Lübbeke A, Rothman KJ, Garavaglia G, Barea C, Christofilopoulos P, Stern R, Hoffmeyer P. Strong association between smoking and the risk of revision in a cohort study of patients with metal-on-metal total hip arthroplasty. J Orthop Res. 2014 Jun;32(6):762-8. doi: 10.1002/jor.22603
Lubbeke A, Garavaglia G, Rothman KJ, Bonvin A, Roussos C, Miozzari H, Hoffmeyer P. Statins may reduce femoral osteolysis in patients with total hip arthroplasty. J Orthop Res. 2013 May 1;31(5):814-20.